You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic

  • Authors: Maurizio Cutolo, MD; Bernard Combe, MD, PhD; Silvio Danese, MD, PhD; Axel Dignass, MD, PhD
  • CPD Released: 7/31/2020
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 7/31/2021
Start Activity


Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US rheumatologists, gastroenterologists, and pharmacists and other healthcare professionals involved in the management of patients with rheumatoid arthritis (RA) and inflammatory bowel disease (IBD).

The goal of this activity is to increase knowledge on the effect of coronavirus disease 2019 (COVID-19) on patients with RA and IBD and the management of these patients on tumor necrosis factor (TNF) inhibitors biosimilars in the COVID-19 pandemic.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • COVID-19 and its impact on patients with RA and IBD
    • Expert guidance on continuation of immunosuppressive therapies in infected patients
  • Demonstrate greater confidence in their ability to
    • Management of RA and IBD patients on TNF inhibitor biosimilars during the COVID-19 pandemic


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Maurizio Cutolo, MD

    Professor of Rheumatology
    University of Genoa School of Medicine
    IRCCS San Martino Polyclinic Hospital
    Genova, Italy

    Disclosures

    Disclosure: Maurizio Cutolo, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
    Served as a speaker or a member of a speakers bureau for: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene
    Received grants for clinical research from: Actelion; Boehringer Ingelheim; Bristol Myers Squibb; Celgene

  • Bernard Combe, MD, PhD

    Head
    Department of Rheumatology
    Montpellier University Hospital
    Montpellier, France

    Disclosures

    Disclosure: Bernard Combe, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Eli Lilly; Gilead Sciences, Inc.; Janssen; Novartis; Roche-Chugai
    Served as a speaker or a member of a speakers bureau for: AbbVie; Bristol Myers Squibb; Eli Lilly; Gilead Sciences, Inc.; Merck Sharp & Dohme; Roche-Chugai
    Received grants for clinical research from: Novartis; Pfizer

  • Silvio Danese, MD, PhD

    Professor of Gastroenterology
    Head of IBD Unit
    Division of Gastroenterolog
    Humanitas University
    Milan, Italy

    Disclosures

    Disclosure: Silvio Danese, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Allergan; Amgen; AstraZeneca; Athos Therapeutics; Biogen; Boehringer Ingelheim; Celgene; Celltrion; Eli Lilly; Enthera; Ferring Pharmaceuticals Inc.; Gilead Sciences, Inc.; Hospira; Inotrem; Janssen; Johnson & Johnson; Merck Sharp & Dohme; Mundipharma; Myland; Pfizer; Roche; Sandoz; Sublimity Therapeutics; Takeda; TiGenix; UCB Inc.

  • Axel Dignass, MD, PhD

    Professor of Medicine and Gastroenterology
    Head
    Department of Medicine I Agaplesion Markus Hospital
    Frankfurt, Germany

    Disclosures

    Disclosure: Axel Dignass, MD, PhD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie; Celgene; Falk; Ferring; Fresnius Kabi; Genentech; Hexal Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Roche; Sandoz; Takeda; Tillotts; Thieme; Vifor
    Served as a speaker or a member of a speakers bureau for: AbbVie; Cilag; Falk; Ferring; Janssen; Med Update GmbH; Merck Sharp & Dohme; Pfizer; Tillotts; Vifor

Editor

  • Walid Amara, MD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: BIOTRONIK; Servier
    Served as a speaker or a member of a speakers bureau for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Livanova; MEDA; Medtronic, Inc.; MSD; Novartis; Pfizer Inc.; Physiomed; St. Jude, Servier, Novartis, Amgen

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Managing Patients on TNF Inhibitors During the COVID-19 Pandemic

Authors: Maurizio Cutolo, MD; Bernard Combe, MD, PhD; Silvio Danese, MD, PhD; Axel Dignass, MD, PhDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CPD Released: 7/31/2020

Valid for credit through: 7/31/2021

processing....

 

 

Video quality may be reduced from our standard offering due to efforts to honor COVID-19 hygienic practices.